Jonathan Kropski Archives
Dec. 20, 2021—Researchers at Vanderbilt University Medical Center have constructed a single-cell “atlas” of lung development that tracks multiple cell types over time.
Why does COVID-19 seem to spare children? Vanderbilt University Medical Center study offers an answer
Nov. 18, 2020—Researchers at Vanderbilt University Medical Center (VUMC) and their colleagues have determined a key factor as to why COVID-19 appears to infect and sicken adults and older people preferentially while seeming to spare younger children.
Jul. 8, 2020—Scientists at Vanderbilt University Medical Center and the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, have discovered previously unreported genetic and cellular changes that occur in the lungs of people with pulmonary fibrosis (PF).
May. 27, 2020—Lung disease experts at Vanderbilt University Medical Center (VUMC) and their colleagues have determined a key factor as to why COVID-19 appears to infect and sicken adults and older people preferentially while seeming to spare younger children.
Nov. 14, 2019—Antiviral immunity, obesity and pulmonary fibrosis will be discussed by three Vanderbilt University researchers during a Cutting-Edge Discovery Lecture on Nov. 21. The lecture will begin at 4 p.m. in 208 Light Hall.
Apr. 18, 2019—Several Vanderbilt faculty members were recently honored during the joint annual meeting of the Association of American Physicians (AAP) and American Society for Clinical Investigation (ASCI).
Mar. 27, 2019—Vanderbilt University Medical Center, the Translational Genomics Research Institute (TGen), an affiliate of City of Hope and the Norton Thoracic Institute at St. Joseph’s Hospital and Medical Center in Arizona, have received a $3.5 million federal grant to study the cause of idiopathic pulmonary fibrosis (IPF) the nation’s most common and severe form of fibrotic lung disease.
Aug. 9, 2018—Two early-career physician-scientists at Vanderbilt University Medical Center are among 18 recipients of 2018 Clinical Scientist Development Awards announced July 31 by the Doris Duke Charitable Foundation.
Feb. 1, 2018—Investigators in the Division of Allergy, Pulmonary and Critical Care have launched a pilot study to see if patients with idiopathic pulmonary fibrosis (IPF) can tolerate the addition of a commonly used antiviral drug to standard IPF treatments. The research team believes the drug may ultimately help slow progression of the chronic and progressive disease or reverse its course.